Lomustine and bevacizumab in progressive glioblastoma

The addition of bevacizumab to lomustine in patients with recurrent glioblastoma failed to increase overall survival but was associated with a small increase in progression-free survival.

Saved in:

Bibliographic Details
Main Authors:	Wick, Wolfgang (Author) , Bendszus, Martin (Author) , Sahm, Felix (Author) , Harting, Inga (Author) , Deimling, Andreas von (Author) , Platten, Michael (Author)
Format:	Article (Journal)
Language:	English
Published:	November 16, 2017
In:	The New England journal of medicine Year: 2017, Volume: 377, Issue: 20, Pages: 1954-1963
ISSN:	1533-4406
DOI:	10.1056/NEJMoa1707358
Online Access:	Verlag, Volltext: http://dx.doi.org/10.1056/NEJMoa1707358 Verlag, Volltext: http://www.nejm.org/doi/pdf/10.1056/NEJMoa1707358
Author Notes:	Wolfgang Wick, Thierry Gorlia, Martin Bendszus, Martin Taphoorn, Felix Sahm, Inga Harting, Alba A. Brandes, Walter Taal, Julien Domont, Ahmed Idbaih, Mario Campone, Paul M. Clement, Roger Stupp, Michel Fabbro, Emilie Le Rhun, Francois Dubois, Michael Weller, Andreas von Deimling, Vassilis Golfinopoulos, Jacoline C. Bromberg, Michael Platten, Martin Klein, Martin J. van den Bent

Description
Summary:	The addition of bevacizumab to lomustine in patients with recurrent glioblastoma failed to increase overall survival but was associated with a small increase in progression-free survival.
Item Description:	Gesehen am 04.12.2017
Physical Description:	Online Resource
ISSN:	1533-4406
DOI:	10.1056/NEJMoa1707358